Home 
CUSTOMERS Bratislava Medical Journal 2022 Bratislava Medical Journal Vol.123, No.6, p.401–407, 2022
CUSTOMERS Bratislava Medical Journal 2022 Bratislava Medical Journal Vol.123, No.6, p.401–407, 2022
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.123, No.6, p.401–407, 2022 |
||
| Title: Immunogenicity and safety of the CoronaVac vaccine in patients undergoing treatment for breast and lung cancer | ||
| Author: Yakup IRIAGAC, Eyyup CAVDAR, Kubilay KARABOYUN, Okan AVCI, Ozkan ALAN, Halil TASKAYNATAN, Aliye CELIKKOL, Sonat Pinar KARA, Berna ERDAL, Erdogan Selcuk SEBER | ||
| Abstract: OBJECTIVE: To compare seroconversion for SARS-CoV-2 receptor-binding domain (RBD) specific IgG positivity against two doses of the CoronaVac vaccine in breast and lung cancer patients receiving systemic therapy, to determine the factors affecting seropositivity, and to observe long-term results up to a secondary booster vaccine. RESULTS: The analysis included 201 cancer patients (99 breasts, 102 lungs; median age: 59 years (range: 28–92), 42.3 % men) and 97 controls (median age: 62 years (range: 24–87), 38.1 % men). The seropositivity rate for RBD IgG after 2 doses of vaccine in the cancer group was 81.6 % (n=164) and 93.8 % (n=91) in the control group (p=0.005). The median IgG titer of cancer patients was significantly lower than in the control group (338 (IQR, 95–933) AU/mL vs 676 (IQR, 389–1270) AU/mL; p<0.001). Multivariate analysis of all the patients determined that having cancer (OR: 0.303, 95%CI: 0.123–0.750, p=0.010) and being over 60 years of age (OR: 0.447, 95%CI: 0.218–0.917, p=0.028) was associated with a reduced vaccine response. A subgroup analysis of cancer patients revealed that seroconversion was lower in men than in women (75.3 % vs 86.2 %, p=0.049) and lower in ≥60 patients than in <60 patients (75.9 % vs 89.4 %, p=0.014). DISCUSSION AND CONCLUSION: Cancer patients receiving an active systemic therapy with two doses of the CoronaVac vaccine had a lower antibody response than the non-cancer population, and deaths due to COVID-19 may occur in these patients despite the vaccine. Therefore, extensive protective measures should be taken to protect against COVID-19 in cancer patients aged 60 years and older, who have received two doses of the CoronaVac vaccine (Tab. 4, Fig. 4, Ref. 27). |
||
| Keywords: vaccine, coronavac, cancer, covid-19, sars-cov-2 | ||
| Published online: 16-May-2022 | ||
| Year: 2022, Volume: 123, Issue: 6 | Page From: 401, Page To: 407 | |
| doi:10.4149/BLL_2022_063 |
||
|
|
 download file |
|